Clinical trial
A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment
NCT05145270 is registered in ClinicalTrials.gov with Shanghai Mental Health Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment
- Lead sponsor
- Shanghai Mental Health Center
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- November 30, 2019
- Completion date
- November 30, 2022
- Enrollment
- 180 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.